Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of MXN 348.21 billion. The enterprise value is 424.04 billion.

Market Cap	348.21B
Enterprise Value	424.04B

Important Dates

The next estimated earnings date is Thursday, July 31, 2025.

Earnings Date	Jul 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.53M
Shares Outstanding	n/a
Shares Change (YoY)	+0.21%
Shares Change (QoQ)	+0.34%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	146.13M

Valuation Ratios

The trailing PE ratio is 11.52 and the forward PE ratio is 8.09.

PE Ratio	11.52
Forward PE	8.09
PS Ratio	1.74
PB Ratio	1.00
P/TBV Ratio	18.58
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.02, with an EV/FCF ratio of 8.51.

EV / Earnings	14.02
EV / Sales	2.29
EV / EBITDA	7.02
EV / EBIT	9.48
EV / FCF	8.51

Financial Position

The company has a current ratio of 1.44, with a Debt / Equity ratio of 0.39.

Current Ratio	1.44
Quick Ratio	0.87
Debt / Equity	0.39
Debt / EBITDA	2.07
Debt / FCF	2.72
Interest Coverage	9.84

Financial Efficiency

Return on equity (ROE) is 9.19% and return on invested capital (ROIC) is 6.48%.

Return on Equity (ROE)	9.19%
Return on Assets (ROA)	5.43%
Return on Invested Capital (ROIC)	6.48%
Return on Capital Employed (ROCE)	10.43%
Revenue Per Employee	26.38M
Profits Per Employee	3.98M
Employee Count	7,605
Asset Turnover	0.36
Inventory Turnover	1.00

Taxes

In the past 12 months, Biogen has paid 5.58 billion in taxes.

Income Tax	5.58B
Effective Tax Rate	15.58%

Stock Price Statistics

The stock price has decreased by -38.53% in the last 52 weeks. The beta is 0.15, so Biogen's price volatility has been lower than the market average.

Beta (5Y)	0.15
52-Week Price Change	-38.53%
50-Day Moving Average	3,373.14
200-Day Moving Average	4,466.92
Relative Strength Index (RSI)	31.96
Average Volume (20 Days)	148

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.06

Income Statement

In the last 12 months, Biogen had revenue of MXN 200.64 billion and earned 30.24 billion in profits. Earnings per share was 206.75.

Revenue	200.64B
Gross Profit	151.78B
Operating Income	48.48B
Pretax Income	35.82B
Net Income	30.24B
EBITDA	62.97B
EBIT	48.48B
Earnings Per Share (EPS)	206.75

Full Income Statement

Balance Sheet

The company has 53.11 billion in cash and 135.33 billion in debt, giving a net cash position of -82.22 billion.

Cash & Cash Equivalents	53.11B
Total Debt	135.33B
Net Cash	-82.22B
Net Cash Per Share	n/a
Equity (Book Value)	347.03B
Book Value Per Share	2,368.78
Working Capital	47.59B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 52.77 billion and capital expenditures -2.96 billion, giving a free cash flow of 49.80 billion.

Operating Cash Flow	52.77B
Capital Expenditures	-2.96B
Free Cash Flow	49.80B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 75.65%, with operating and profit margins of 24.16% and 15.07%.

Gross Margin	75.65%
Operating Margin	24.16%
Pretax Margin	17.85%
Profit Margin	15.07%
EBITDA Margin	31.39%
EBIT Margin	24.16%
FCF Margin	24.82%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.21%
Shareholder Yield	n/a
Earnings Yield	8.68%
FCF Yield	14.30%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogen has an Altman Z-Score of 3.17 and a Piotroski F-Score of 6.

Altman Z-Score	3.17
Piotroski F-Score	6